Friday, July 10, 2026

Drug profile · INN

topiramate

topiramate (APO-TOPIRAMATE) is a gaba-a receptor; anion channel positive modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved TGA: approved PMDA: approved
US status approved
Patents linked 20
Pipeline programs 25
News articles 0
Drug details — topiramate
US status
approved
Class
Route
ORAL
Patents
20
Programs
25
Data quality
0.89

Quick answer

topiramate (APO-TOPIRAMATE) is a gaba-a receptor; anion channel positive modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN topiramate
Brand APO-TOPIRAMATE
Mechanism GABA-A receptor; anion channel positive modulator
Target Carbonic anhydrase 2
Route ORAL
Formulation CAPSULE

Mechanism of action

GABA-A receptor; anion channel positive modulator

Primary target: Carbonic anhydrase 2

Approval history

Authority Status Date
FDA approved
TGA approved
PMDA approved

Pipeline programs

  1. PEDIADEX Phase 3 · Tour Hekla · Impact on delirium of the use of DEXmedetomidine as first-l
  2. Topiramate + Cognitive Behavioral Therapy Phase 3 · BRIGHT MINDS BIOSCIENCES · Cocaine-Related Disorders
  3. topiramate Phase 3 · Ultragenyx UK · Lennox-Gastaut Syndrome
  4. 2026-525211-14-00 Phase 2 · Disc Medicine · HIV-1
  5. Adderall-XR and Topiramate Phase 2 · BRIGHT MINDS BIOSCIENCES · Cocaine Dependence
  6. IR-TPM (Topamax) Phase 2 · SUPERNUS PHARMACEUTICALS · Migraine
  7. OXY-APS Phase 2 · George Institute for · schizophrenia or other primary psychotic disorders (SSD)
  8. TOPIRAMATE Phase 2 · Disc Medicine · human immunodeficiency virus 1 (HIV-1)

Related & competitor drugs

  1. dorzolamide hydrochloride Carbonic anhydrase II inhibitor
  2. brinzolamide Sensory organs (S01)
  1. US 12180251

    Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11969470

    Topiramate compositions and methods of making and using the same

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11787839

    Targeting α2δ-1-bound glutamate receptors for treating diseases and disorders

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11447453

    Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11071787

    Topiramate compositions and methods of making and using the same

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10597367

    Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10398668

    Glutamate treatment of cardiovascular disorders

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10377695

    Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10314790

    Sustained-release formulations of topiramate

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 9765091

    Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 9744137

    Topiramate compositions and methods of enhancing its bioavailability

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 9622983

    Sustained-release formulations of topiramate

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 9555004

    Sustained-release formulations of topiramate

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9549940

    Sustained-release formulations of topiramate

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9073907

    Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 8992989

    Sustained-release formulations of topiramate

    Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 8889191

    Sustained-release formulations of topiramate

    Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8883826

    Alkynyl derivatives as modulators of metabotropic glutamate receptors

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 8877248

    Sustained-release formulations of topiramate

    Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8697744

    Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is topiramate?

topiramate (APO-TOPIRAMATE) is a gaba-a receptor; anion channel positive modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for topiramate?

APO-TOPIRAMATE is a marketed brand name for topiramate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of topiramate?

topiramate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.